Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hypertension: full-pipeline trial registry
152 of 472 indexed Hypertension trials are currently recruiting.
Corpus placement: #8 of 28,707 conditions by registered trial count.
472 US clinical trials · 152 currently recruiting · #8 of 28,707 conditions by registered trial count
Hypertension: 472 US clinical trials tracked, 152 recruiting.
Hypertension is the subject of 472 registered US clinical trials on ClinicalTrials.gov, 152 of them currently open to new participants. 65 are in Phase 3-4 (later-stage) and 64 in Phase 1-2 (earlier-stage). The most active sponsor is Johns Hopkins University, running 15 of these trials.
Enrollment posture brief
Registry condition hypertension
OPEN 152 | RECR 32% | LATE 65 | EARLY 64 | RANK #8 | SPON 15
Volume-matched condition peers
Nearest open-share peer: Leukemia, Myeloid, Acute (32% recruiting · 31 trials)
Hypertension lists 152 open slots (32% of 472 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hypertension on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hypertension is recruiting below its size-band peers.
152 of 472 indexed trials (32.2%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Hypertension trials is spread across many organizations.
Johns Hopkins University accounts for 15 of 472 trials (3.2%). 195 distinct sponsors appear on at least one study for this condition label.
-
Typical Hypertension enrolment sits around 168 participants.
Median target enrolment is 168 among the 471 trials that report a genuine target (sentinel values excluded). 170 of those (36.1%) plan for fewer than 100 participants.
-
Hypertension research is mostly interventional.
407 interventional and 65 observational studies make up this index (86.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
472 total, page 6 of 10
Olmesartan Comparison to Losartan in Hypertensive Subjects
Daiichi Sankyo
NCT00949884
A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly
Novartis Pharmaceuticals
NCT00368277
Effect of Intense vs. Standard Hypertension Management on Nighttime Blood Pressure - an Ancillary Study to SPRINT
University of Minnesota
NCT01835249
Clinician Counseling and Cultural Competency to Improve Hypertension Control and Therapy Adherence
Boston Medical Center
NCT00201149
A Clinical Study to Compare an Aliskiren Based Hypertensive Regimen With a Ramipril Based One Followed by a Randomized Withdrawal.
Novartis
NCT00219063
12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus
Boehringer Ingelheim
NCT01370005
A Study of the Safety and Efficacy of Nebivolol in Hypertensive Patients
Mylan Bertek Pharmaceuticals
NCT00200473
Electronic Communications and Home Blood Pressure Monitoring
Kaiser Permanente
NCT00158639
Physician Uncertainty Reduction for Hypertension
Baylor College of Medicine
NCT00201084
Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Patients With Stage II Hypertension
Novartis
NCT00350168
The CREATE Wellness Study
Kaiser Permanente
NCT02302612
Study of the Efficacy and Safety of Nebivolol in Younger Patients (18 - 54 Years)
Forest Laboratories
NCT01415531
Improving Adherence to Blood Pressure Guidelines
University of Iowa
NCT00201019
Hypertension Intervention Nurse Telemedicine Study (HINTS)
US Department of Veterans Affairs
NCT00237692
Targeting of UnControlled Hypertension in Emergency Department
University of Illinois at Chicago
NCT03749499
Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension
Takeda
NCT00591266
Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension
Takeda
NCT00591773
Study to Lower Veterans BP: Patient/Physician Intervention
US Department of Veterans Affairs
NCT00105716
Hypertension With Unsatisfactory Sleep Health
University of Pittsburgh
NCT02508129
Improving Care for Patients With High Blood Pressure
University of North Carolina, Chapel Hill
NCT01425515
Personalizing Intervention to Reduce Clinical Inertia in the Treatment of Hypertension
Brigham and Women's Hospital
NCT04603560
Blood Sampling for Neurochemical and Genetic Testing
National Institute of Neurological Disorders and Stroke (NINDS)
NCT00001147
Potential Risk Factors for Stroke
National Institute of Neurological Disorders and Stroke (NINDS)
NCT00001368
Center for Stroke Disparities Solution - Community Transitions Intervention
Visiting Nurse Service of New York
NCT01918891
Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose
Boehringer Ingelheim
NCT00034840
Methods for Measuring Insulin Sensitivity
National Center for Complementary and Integrative Health (NCCIH)
NCT00001625
Unmet Social Needs Study
VA Office of Research and Development
NCT04977583
SPHERE Hypertension Baseline Data Study
University of Washington
NCT00444496
Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension
Novartis Pharmaceuticals
NCT00219141
Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension
Novartis Pharmaceuticals
NCT01692301
Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension
Takeda
NCT00362115
Using an Electronic Personal Health Record to Empower Patients With Hypertension
Augusta University
NCT01317537
Novartis - Closing the Gap in Cardiovascular Risk: Engage, Empower, Evaluate
Rush University Medical Center
NCT06027905
Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine Versus Amlodipine Alone in African American Patients With Stage 2 Hypertension
Novartis
NCT00853957
SupportBP 2.0:Behavioral Science and Enrollment in Remote Monitoring for Hypertension Management
University of Pennsylvania
NCT04714398
Efficacy and Safety of Valsartan and the Combination of Valsartan and Simvastatin
Novartis
NCT00385931
The Health Access and Recovery Peer Program
Emory University
NCT01725815
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension
Alnylam Pharmaceuticals
NCT04936035
The GoodNEWS Lifestyle Enhancement Program
University of Texas Southwestern Medical Center
NCT00669630
An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension
Arbor Pharmaceuticals
NCT02235909
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
Novartis Pharmaceuticals
NCT01876368
A 10-12 Week Study to Evaluate the Safety and Efficacy of 320 mg Valsartan and 80 mg Simvastatin in Combination and as Monotherapies in Treating Hypertension and Hypercholesterolemia
Novartis
NCT00171093
Health Literacy-Focused Program to Improve Blood Pressure Control in Korean Americans
University of Texas at Austin
NCT00406614
Project IMPACT: CHW Intervention
NYU Langone Health
NCT03159533
Socioeconomic Status, Psychosocial Factors, and CVD Risk in Mexican-American Women
San Diego State University
NCT00387166
The SCCS Polypill Pilot Trial
Vanderbilt University
NCT02278471
Effectiveness of Patient-centered Community Health Worker Support to Help Patients Control Chronic Disease
University of Pennsylvania
NCT01900470
Men Together Making a Difference: Health Promotion for Black Men
University of Pennsylvania
NCT02572414
Effectiveness of Home-Based Health Messaging for Patients With Hypertension and Diabetes
US Department of Veterans Affairs
NCT00119054
Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension
Novartis
NCT00277472
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 39 |
| Phase 2 | 25 |
| Phase 3 | 37 |
| Phase 4 | 28 |
Top Sponsors
Named interventions
Most-linked intervention names on Hypertension records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hypertension trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hypertension page
472 registered trials, 152 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 152 Hypertension trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Johns Hopkins University sponsors the most Hypertension trials on record, review their full trial history before evaluating a specific study. See Johns Hopkins University's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hypertension condition card totals 472 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.